Immunome, Inc. (IMNM)

Immunome, Inc. (IMNM) stock has experienced significant events and volatility in the past six months. As of January 7, 2026, the share price was $19.98, an 87.43% increase from January 8, 2025. The stock's weekly volatility is 12%. Key events include proposed and completed public offerings, clinical trial updates for Varegacestat and IM-1021, presentations at investor and healthcare conferences, and a research collaboration with Infinimmune.

There is limited data to establish a reliable seasonal demand profile for Immunome, Inc. (IMNM) products and services. The broader Healthcare sector has shown seasonal strength from April 25 to December 4. Analysis of seasonal charts suggests a "Buy Date" of June 20 and a "Sell Date" of September 30, resulting in a geometric average return of 42.97% above the S&P 500 Total Return Index benchmark.

Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted cancer therapies, operating within the Biotechnology & Medical Research industry. The company utilizes a proprietary human memory B cell platform to identify novel antibodies and targets. Its portfolio includes immunotherapies, radioligand therapies, and Antibody-Drug Conjugates (ADCs). Key product candidates include Varegacestat, a late-clinical stage gamma secretase inhibitor in Phase 3 trials for desmoid tumors with topline data expected in the second half of 2025; IM-1021, a ROR1-targeted ADC in Phase 1 showing objective responses in B-cell lymphoma patients; IM-3050, a FAP-targeted radioligand therapy with a Phase 1 study planned for early 2026; and preclinical ADCs like IM-1617, IM-1340, and IM-1335 pursuing undisclosed targets in solid tumors.

Immunome, Inc. operates in the United States and is headquartered in Bothell, Washington. The company was founded in 2006 in Philadelphia.

Immunome's brand reputation has been positively influenced by advancements in clinical trials and participation in key industry events. Progress in the Phase 3 RINGSIDE trial for varegacestat and the Phase 1 trial for IM-1021, along with presentations at investor and healthcare conferences, have contributed to a positive perception. A research collaboration with Infinimmune also suggests positive industry engagement.

Immunome, Inc. (IMNM) has a diverse ownership structure, with approximately 46.18% to 82.78% of the stock held by institutional investors, 10.77% to 15.71% by individual investors and public companies, and about 1.51% by insiders. Major institutional owners include Fmr Llc, T. Rowe Price Investment Management, Inc., BlackRock, Inc., Redmile Group, LLC, and Vanguard Group Inc.